Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsMichael Brian Fessler, Carmen J. Williams, Wan-Chi Lin
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating or preventing a lung disorder comprising administering to a subject a composition comprising an agent that modulates activity and/or expression of Epithelial Membrane Protein 2 (EMP2) in an amount effective to treat or prevent the lung disorder and compositions useful in such for methods.
Claims11
A method of treating or preventing a lung disorder in a subject in need thereof, comprising administering to the subject a composition comprising an agent that modulates the activity and/or expression of Epithelial Membrane Protein 2 (EMP2),
- wherein the agent is
- (a) an anti-EMP2 antibody selected from the group consisting of PG101, KS83, KS49, KS41, KS89, and a combination thereof, or an antigen-binding fragment thereof;
- or
- (b) a small interfering RNA (siRNA) capable of binding to an EMP2-encoding nucleotide sequence;
- or
- (c) an antisense oligonucleotide capable of binding to the EMP2-encoding nucleotide sequence, and
- wherein the lung disorder is
- (i) an acute disease selected from the group consisting of acute lung injury, acute respiratory distress syndrome, pneumonia, viral infection, and airway hyperresponsiveness;
- (ii) a neutrophil-dependent lung disorder;
- (iii) an epithelial lipid raft-dependent and/or caveolae-dependent lung disease;
- (iv) a TGF-β (Transforming growth factor beta)-mediated lung disorder selected from the group consisting of pulmonary fibrosis and acute lung injury;
- (v) an eosinophil-dependent lung disorder selected from the group consisting of asthma, acute eosinophilic pneumonia, and chronic eosinophilic pneumonia;
- or a monocyte-dependent lung disorder selected from the group consisting of lung fibrosis and acute lung injury;
- or a lymphocyte-dependent lung disorder selected from the group consisting of lymphocytic interstitial pneumonia and lymphocytic bronchiolitis;
- (vi) idiopathic pulmonary fibrosis comprising epithelium-matrix interaction;
- (vii) a chronic disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), bronchiectasis, radiation- or chemotherapeutic-induced pneumonitis, idiopathic or induced interstitial lung disease, bronchopulmonary dysplasia, and lung fibrosis;
- (viii) a lung disorder due to exposure to a toxic agent selected from the group consisting of a bioterroristic agent, an occupational hazardous agent and an environmental pollutant or
- (ix) chemical pneumonitis due to chemical or acid or hydrocarbon aspiration;
- or chemical pneumonitis due to smoke inhalation.
A method to target a molecule to alveolar epithelial type 1 cells in a subject with a lung disorder comprising co-administering the molecule with an agent that binds EMP2,
- wherein the agent is an anti-EMP2 antibody selected from the group consisting of PG101, KS83, KS49, KS41, KS89, and a combination thereof, or an antigen-binding fragment thereof,
- wherein the lung disorder is
- (i) an acute disease selected from the group consisting of acute lung injury, acute respiratory distress syndrome, pneumonia, viral infection, and airway hyperresponsiveness;
- (ii) a neutrophil-dependent lung disorder;
- (iii) an epithelial lipid raft-dependent and/or caveolae-dependent lung disease;
- (iv) a TGF-β (Transforming growth factor beta)-mediated lung disorder selected from the group consisting of pulmonary fibrosis and acute lung injury;
- (v) an eosinophil-dependent lung disorder selected from the group consisting of asthma, acute eosinophilic pneumonia, and chronic eosinophilic pneumonia;
- or a monocyte-dependent lung disorder selected from the group consisting of lung fibrosis and acute lung injury;
- or a lymphocyte-dependent lung disorder selected from the group consisting of lymphocytic interstitial pneumonia and lymphocytic bronchiolitis;
- (vi) idiopathic pulmonary fibrosis comprising epithelium-matrix interaction;
- (vii) a chronic disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), bronchiectasis, radiation- or chemotherapeutic-induced pneumonitis, idiopathic or induced interstitial lung disease, bronchopulmonary dysplasia, and lung fibrosis;
- (viii) a lung disorder due to exposure to a toxic agent selected from the group consisting of a bioterroristic agent, an occupational hazardous agent and an environmental pollutant or
- (ix) chemical pneumonitis due to chemical or acid or hydrocarbon aspiration;
- or chemical pneumonitis due to smoke inhalation.
Dependencies are inferred from the claim text.